No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CMND Clearmind Medicine
- 2.2200
- +0.5200+30.59%
Close Jul 15 16:00 ET
- 2.1300
- -0.0900-4.05%
Pre 04:47 ET
7.35MMarket Cap-566P/E (TTM)
2.3000High1.7300Low3.01MVolume1.7300Open1.7000Pre Close6.20MTurnover92.52%Turnover RatioLossP/E (Static)3.31MShares16.194052wk High1.58P/B7.23MFloat Cap0.920552wk Low--Dividend TTM3.26MShs Float183.0000Historical High--Div YieldTTM33.53%Amplitude0.9205Historical Low2.0580Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Clearmind Medicine To Present Research At Psychedelic Medicine – Israel 2024 Conference
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
Vancouver, Canada, July 12, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel
Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine Inc. (NASDAQ:CMND) shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of pa
Express News | Clearmind Medicine Shares Are Trading Higher After the Company Announced Advancement in Its Proprietary MEAI- Based Binge Behavior Regulator Program Through the Granting of Patent Approval in Hong Kong by the Hong Kong Patent Office
Express News | Clearmind Medicine Granted Patent Approval In Hong Kong For Its Binge Behaviors Treatment, Which Builds Upon Company's Broad IP Protection In The Psychedelic Space
Express News | Clearmind Medicine Shares Are Trading Higher After the Company Signed an Exclusive Patent Licensing Agreement With Yissum Research Development Company of the Hebrew University of Jerusalem
Comments
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference.
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotechnology firm dedicated to the discovery and development of novel psychedelic-derived therapeutics, has announced its participation in the forthcoming Psychedelic Medicine – Israel 2024 conference. This event will be he...
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotechnology firm dedicated to the discovery and development of novel psychedelic-derived therapeutics, has announced its participation in the forthcoming Psychedelic Medicine – Israel 2024 conference. This event will be he...
1
$Clearmind Medicine(CMND.US$ finally after half month！！
1
$Clearmind Medicine(CMND.US$ when? any specific day?
$Clearmind Medicine(CMND.US$
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, will present significant research at the Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28-30. CEO Adi Zullof-Shani, Ph.D., will discuss the potential of 5-Methoxy-2-Aminoindane (MEAI) as a regulator of binge behaviors on July 29. Additionally, researchers Prof. Joseph Tam an...
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, will present significant research at the Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28-30. CEO Adi Zullof-Shani, Ph.D., will discuss the potential of 5-Methoxy-2-Aminoindane (MEAI) as a regulator of binge behaviors on July 29. Additionally, researchers Prof. Joseph Tam an...
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg